Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 26 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Severe Side Effects of Cancer Treatment Are More Common in Women... March 15, 2022 Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers October 19, 2021 After Being Told a Lump Was Benign, Teenager Learns She Has... August 14, 2021 Load more HOT NEWS TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... Breast Cancer Survivor Fights Back After Instagram Bans Photos of Her...
